Add up to five of your favourite RCPsych pages to find them whenever you need.
You currently have no favourites. Visit and add pages to access them here.
Gabapentinoids in psychiatric practice: Balancing the risks and benefits
Position Statement PS03/25, October 2025
This joint position statement by the Psychopharmacology Committee of the Royal College of Psychiatrists and the British Association for Psychopharmacology provides clinicians with guidance on prescribing, monitoring and withdrawing from gabapentinoids safely.
It aims to raise awareness of the potential risks associated with the use of these medicines, including non-prescribed use, adverse effects and withdrawal symptoms, and encourages partnership with patients.